Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 986 participants.

Also called NCT01177813

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 986 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01177813
  • EudraCT 2009-016243-20
Other papers using this trial's data
  • Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial The lancet. Diabetes & endocrinology, 2013-11 DOI, PubMed 24622369

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
Not reported
Results first posted
(from the registry)
Countries
United States, Belgium, Canada, China, Germany, India, Ireland, Japan, Switzerland (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01177813. Randomized; double masking; primary purpose treatment. Start 2010-07 (registry gives no type); primary completion 2012-03 (actual). Results posted on 2014-06-16.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Empagliflozin (BI 10773) Versus Placebo and Sitagliptin Over 24 Weeks in Patients With Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
Placebo identical to BI10773 high dose
Intervention (Drug)
BI 10773
Intervention (Drug)
BI 10773 open label
Intervention (Drug)
Placebo identical to BI10773 low dose
Intervention (Drug)
Placebo identical to BI10773 low dose
Intervention (Drug)
Placebo identical to BI10773 high dose
Intervention (Drug)
Placebo identical to Sitagliptin 100mg
Intervention (Drug)
Placebo identical to Sitagliptin 100mg
Intervention (Drug)
BI10773
Intervention (Drug)
Sitagliptin
Intervention (Drug)
Placebo identical to Sitagliptin 100mg
Intervention (Drug)
Placebo identical to BI10773 low dose
Intervention (Drug)
Placebo identical to BI10773 high dose
Lead sponsor
Boehringer Ingelheim (class: industry)
Collaborator
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01177813
Content hash
a03351a0de2d9300915c6fb863ae6ff8766691e60e5ea41708dcdafccbbf84ef